Literature DB >> 15133856

Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.

Zhong-Sheng Zhu1, Jin-Ming Wang, Shao-Liang Chen.   

Abstract

AIM: To investigate the remodeling of mesenteric artery and the expression of TGF-beta1, c-Jun in mesenteric artery and effects of imidapril and irbesartan on the remodeling in spontaneously hypertensive rats (SHR).
METHODS: Thirty SHR (male/female, 21/9), aged 13 wk, were randomly divided into 3 groups (7 male rats and 3 female rats each group): SHR group, imidapril group (imidapril 3 mg/kg.d was given in drinking water for 14 wk), and irbesartan group (irbesartan 50 mg/kg.d was given in drinking water foe 14 wk). Ten homogeneous Wistar Kyoto rats, 5 males and 5 females, weighing 206+/-49 g, were selected as normal control group (WKY group). Systolic pressure was measured on d 1, 2, 4, 6, 8, 10, 12 and 14 during the experiment and the rats were killed at the end of the experiment. Angiotensin II (Ang II) level in plasma and mesenteric arteries was measured by radioimmunoassay. The morphology of the secondary branches of mesenteric artery were examined by light microscopy and electron microscopy. Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expression of transforming growth factor TGF-beta1 and c-Jun mRNA.
RESULTS: Compared with imidapril group and irbesartan group, the blood pressure was remarkably increased in SHR group. Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group. The remodeling of mesenteric arteries in SHR group was mostly obvious among the 4 groups. The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01). Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05). The c-Jun absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).
CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR. Imidapril is more effective than irbesartan.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133856      PMCID: PMC4656287          DOI: 10.3748/wjg.v10.i10.1471

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells.

Authors:  Michael Gekle; Petra Knaus; Rikke Nielsen; Sigrid Mildenberger; Ruth Freudinger; Verena Wohlfarth; Christoph Sauvant; Erik I Christensen
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

2.  Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells.

Authors:  K Iizuka; T Murakami; H Kawaguchi
Journal:  Biochem Biophys Res Commun       Date:  2001-05-04       Impact factor: 3.575

Review 3.  Angiotensin II and the pathophysiology of cardiovascular remodeling.

Authors:  B Williams
Journal:  Am J Cardiol       Date:  2001-04-19       Impact factor: 2.778

4.  Growth factors and extracellular signal-regulated kinase in vascular smooth muscle cells of normotensive and spontaneously hypertensive rats.

Authors:  O Ebisui; R J Dilley; H Li; J W Funder; J P Liu
Journal:  J Hypertens       Date:  1999-11       Impact factor: 4.844

Review 5.  Aldosterone: a risk factor for vascular disease.

Authors:  Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 6.  Molecular mechanisms of angiotensin II-induced vascular injury.

Authors:  Marta Ruiz-Ortega; Monica Ruperez; Vanesa Esteban; Jesús Egido
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 7.  Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling.

Authors:  P J Lijnen; V V Petrov
Journal:  Methods Find Exp Clin Pharmacol       Date:  2003-09

8.  Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors.

Authors:  Bishoy Rizkalla; Josephine M Forbes; Mark E Cooper; Zemin Cao
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

9.  Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK.

Authors:  U Schmitz; T Ishida; M Ishida; J Surapisitchat; M I Hasham; S Pelech; B C Berk
Journal:  Circ Res       Date:  1998-06-29       Impact factor: 17.367

10.  Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.

Authors:  Dilek Yavuz; Mehmet Koç; Ahmet Toprak; Ihsan Akpinar; Ayliz Velioğlu; Oguzhan Deyneli; Goncagül Haklar; Sema Akalin
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-09       Impact factor: 1.636

View more
  2 in total

1.  Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling.

Authors:  Tony E Walshe; Vandana S Dole; Arindel S R Maharaj; Ian S Patten; Denisa D Wagner; Patricia A D'Amore
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-21       Impact factor: 8.311

2.  Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.

Authors:  M R Jones; K A Schrader; Y Shen; E Pleasance; C Ch'ng; N Dar; S Yip; D J Renouf; J E Schein; A J Mungall; Y Zhao; R Moore; Y Ma; B S Sheffield; T Ng; S J M Jones; M A Marra; J Laskin; H J Lim
Journal:  Ann Oncol       Date:  2016-02-18       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.